Circulating extracellular vesicle lipidomics identifies distinct signatures of amyotrophic lateral sclerosis and spinal muscular atrophy
- 1Vesalic Limited, London, UK
Abstract
Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative disorder lacking established biomarkers of underlying disease biology. Here, we identify lipidomic signatures of circulating extracellular vesicles (EVs) that distinguish ALS from neurologically healthy controls and related neuromuscular diseases. Using mass spectrometry-based profiling and multivariate modelling, we separate ALS (n=77) from healthy controls (n=89) with an area under the receiver operating characteristic curve (AUROC) of 0.90 (95% CI 0.85-0.94), rising to 0.92 (0.89-0.96) when low-confidence predictions are withheld, and retaining performance in an independent cohort (n=119; AUROC 0.78, 0.70-0.86). In Tofersen-treated SOD1-ALS patients, biomarker trajectories change in parallel with clinical measures while individuals with spinal muscular atrophy (n=50) exhibit a lipid fingerprint distinct from that observed in ALS, supporting disease specificity within a shared systemic framework of abnormal systemic lipogenesis. These findings establish EV-associated lipid signatures as a systemic, blood-based biomarker platform for ALS diagnosis, stratification, and treatment monitoring, with structurally distinct lipid species indicating widespread membrane remodelling.
Related
- Serum lipidomics identifies outcome signatures in patients with traumatic brain injury, presenting with Glasgow Coma Scale score of 13-15
- Circulating insulin-like growth factor 1 (IGF-1) and short-term functional change in amyotrophic lateral sclerosis (ALS): exploratory evidence for systemic trophic-metabolic reserve.
- Circulating extracellular vesicles display immunotherapeutic targets and complement circulating tumor DNA in high-risk neuroblastoma
- Multivariate analysis identifies distinct latent components and highlights the contribution of motor cortex neurochemistry to clinical variance in amyotrophic lateral sclerosis
- Genetic and circulating inflammatory cytokine signatures for renal cell carcinoma risk: a case-control study from Northwest China
BibTeX
@misc{ricotti2026circulating,
title = {{Circulating extracellular vesicle lipidomics identifies distinct signatures of amyotrophic lateral sclerosis and spinal muscular atrophy}},
author = {V. Ricotti and A. Fogel and M. Vandenbosch and F. Cerri and P. Ala and A. Capstick and R. Rossi and F. Gerardi and R. Jacobs and E. Mercuri and V. Sansone and P. J. Shaw and P. Barnaghi and T. Voit},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.23.26363372},
url = {https://www.medrxiv.org/content/10.64898/2026.09.23.26363372v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Circulating extracellular vesicle lipidomics identifies distinct signatures of amyotrophic lateral sclerosis and spinal muscular atrophy
AU - V. Ricotti
AU - A. Fogel
AU - M. Vandenbosch
AU - F. Cerri
AU - P. Ala
AU - A. Capstick
AU - R. Rossi
AU - F. Gerardi
AU - R. Jacobs
AU - E. Mercuri
AU - V. Sansone
AU - P. J. Shaw
AU - P. Barnaghi
AU - T. Voit
PY - 2026
DA - 2026/09/23
PB - medRxiv
DO - 10.64898/2026.09.23.26363372
UR - https://www.medrxiv.org/content/10.64898/2026.09.23.26363372v1
AB - Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative disorder lacking established biomarkers of underlying disease biology. Here, we identify lipidomic signatures of circulating extracellular vesicles (EVs) that distinguish ALS from neurologically healthy controls and related neuromuscular diseases. Using mass spectrometry-based profiling and multivariate modelling, we separate ALS (n=77) from healthy controls (n=89) with an area under the receiver operating characteristic curve (AUROC) of 0.90 (95% CI 0.85-0.94), rising to 0.92 (0.89-0.96) when low-confidence predictions are withheld, and retaining performance in an independent cohort (n=119; AUROC 0.78, 0.70-0.86). In Tofersen-treated SOD1-ALS patients, biomarker trajectories change in parallel with clinical measures while individuals with spinal muscular atrophy (n=50) exhibit a lipid fingerprint distinct from that observed in ALS, supporting disease specificity within a shared systemic framework of abnormal systemic lipogenesis. These findings establish EV-associated lipid signatures as a systemic, blood-based biomarker platform for ALS diagnosis, stratification, and treatment monitoring, with structurally distinct lipid species indicating widespread membrane remodelling.
ER -